

related to a disease state comprising:

at least one biochemical material which is capable of specifically binding with a biomolecule which includes at least one biopolymer marker selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or at least one analyte thereof related to said disease state; and

means for determining binding between said biochemical material and said biomolecule;

whereby at least one analysis to determine a presence of a marker, analyte thereof, or a biochemical material specific thereto, is carried out on a sample.

29. Polyclonal antibodies produced against a marker sequence ID selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or at least one analyte thereof in at least one animal host.

30. An antibody that specifically binds a biopolymer including a marker selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or at least one analyte thereof.

33. A process for identifying therapeutic avenues related to a disease state comprising:
conducting an analysis as provided by the kit of claim 18; and
interacting with a biopolymer selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or at least one analyte thereof;

whereby therapeutic avenues are developed.

25 34. The process for identifying therapeutic avenues related to a disease state in accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or at least one analyte thereof.

26 38. A process for regulating a disease state by controlling the presence or absence of a biopolymer selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or at least one analyte thereof.

REMARKS

The foregoing Supplemental Preliminary Amendment is made in conjunction with the simultaneous entry of the response to the Notice to Comply with Requirements for Patent Applications, filed concurrently herewith, so as to further bring this application into conformance with Rules 37 CFR §1.821 - 1.825. No new matter is added. Examination on the merits is respectfully requested.